Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 1,110 -3.45%
19 Feb 4:01 p.m.
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.

Website BSE NSE
  • Market Cap ₹ 11,609 Cr.
  • Current Price ₹ 1,110
  • High / Low ₹ 2,150 / 1,100
  • Stock P/E 36.6
  • Book Value ₹ 174
  • Dividend Yield 0.95 %
  • ROCE 28.4 %
  • ROE 21.4 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 18.7% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 28.2%

Cons

  • Company has high debtors of 159 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE Allcap BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
241 273 195 262 241 319 216 310 244 430 204 247 278
129 144 123 143 135 185 135 174 146 239 143 157 176
Operating Profit 112 129 72 119 106 134 81 137 98 190 61 91 102
OPM % 46% 47% 37% 45% 44% 42% 38% 44% 40% 44% 30% 37% 37%
9 12 7 8 8 11 10 10 15 9 14 13 7
Interest 1 1 1 1 0 0 0 0 0 0 0 0 0
Depreciation 14 14 13 13 14 14 13 13 13 15 18 18 19
Profit before tax 106 126 65 113 100 131 78 133 99 185 57 86 90
Tax % 26% 26% 25% 25% 26% 26% 25% 26% 25% 23% 26% 26% 25%
79 94 48 84 75 97 58 99 74 142 43 63 68
EPS in Rs 7.56 8.94 4.63 8.08 7.13 9.29 5.57 9.43 7.08 13.57 4.07 6.01 6.48
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
239 276 340 436 512 617 713 853 1,017 1,200 1,159
133 145 212 256 308 289 439 509 585 693 714
Operating Profit 105 131 127 180 205 328 274 344 432 507 445
OPM % 44% 48% 37% 41% 40% 53% 38% 40% 42% 42% 38%
11 8 36 17 31 14 23 35 34 44 43
Interest 1 0 1 1 1 1 6 5 3 1 0
Depreciation 10 10 18 19 21 28 50 54 54 54 69
Profit before tax 106 129 144 178 213 313 241 320 409 496 418
Tax % 34% 33% 30% 33% 21% 25% 26% 26% 26% 25%
70 87 100 118 169 235 179 238 305 373 315
EPS in Rs 76.32 94.78 105.66 124.48 177.65 247.44 187.76 22.76 29.13 35.65 30.13
Dividend Payout % 22% 25% 0% 21% 22% 0% 3% 30% 30% 25%
Compounded Sales Growth
10 Years: 18%
5 Years: 19%
3 Years: 19%
TTM: 6%
Compounded Profit Growth
10 Years: 18%
5 Years: 19%
3 Years: 27%
TTM: -3%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -32%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 21%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 9 9 10 10 10 10 10 10 10 10 10
Reserves 268 329 585 673 761 990 1,098 1,282 1,515 1,802 1,815
35 36 22 9 52 89 62 32 10 3 2
55 74 69 71 118 94 144 191 164 219 194
Total Liabilities 367 448 685 763 941 1,183 1,313 1,515 1,699 2,034 2,021
104 110 189 230 240 546 573 593 575 795 790
CWIP 19 70 3 19 141 18 74 173 211 51 74
Investments 42 43 151 229 199 142 74 138 244 335 354
202 225 343 285 361 477 592 611 668 854 804
Total Assets 367 448 685 763 941 1,183 1,313 1,515 1,699 2,034 2,021

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
79 155 167 207 246 265 245
-42 -114 -195 -112 -158 -155 -160
-37 -43 31 -100 -85 -99 -99
Net Cash Flow 0 -1 3 -4 3 12 -14

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 165 182 236 133 131 105 119 117 125 159
Inventory Days 276 321 381 310 312 503 434 430 331 286
Days Payable 108 129 210 112 201 152 185 190 150 135
Cash Conversion Cycle 334 374 407 331 242 456 368 357 306 310
Working Capital Days 195 209 275 177 159 177 163 153 166 193
ROCE % 37% 25% 25% 32% 21% 26% 28% 28%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08%
7.30% 7.00% 6.49% 7.11% 8.10% 8.33% 9.35% 9.10% 8.03% 7.58%
8.12% 8.40% 8.41% 10.35% 9.82% 9.65% 9.16% 8.85% 9.55% 9.58%
40.50% 40.52% 41.03% 38.46% 38.02% 37.93% 37.41% 37.94% 38.32% 38.75%
No. of Shareholders 1,00,92787,48683,29680,73784,29882,00481,21982,04582,65081,815

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls